Marina Biotech

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Marina Biotech headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $2.8B in funding across 112 round(s). With a team of 11-50 employees, Marina Biotech is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Marina Biotech, raised $6.0M. Discover more about their projects, partnerships, and impact on our platform.